[{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ONCT-534","moa":"Androgen N-terminal domain receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Oncternal Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ONCT-534","moa":"Androgen N-terminal domain receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Oncternal Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Center for Cancer Research","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ONCT-534","moa":"Androgen N-terminal domain receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Oncternal Therapeutics \/ Center for Cancer Research","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal Therapeutics \/ Center for Cancer Research"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ONCT-534","moa":"Androgen N-terminal domain receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Oncternal Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ONCT-534","moa":"Androgen N-terminal domain receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Oncternal Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ONCT-534","moa":"Androgen N-terminal domain receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncternal Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ONCT-534","moa":"Androgen N-terminal domain receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncternal Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ONCT-534","moa":"Androgen N-terminal domain receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncternal Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ONCT-534","moa":"Androgen N-terminal domain receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncternal Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Oncternal Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Cirmtuzumab","moa":"Inactive tyrosine-protein kinase transmembrane receptor ROR1","graph1":"Oncology","graph2":"Phase II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncternal Therapeutics \/ Oncternal Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Oncternal Therapeutics \/ Oncternal Therapeutics"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Cirmtuzumab","moa":"||Inactive tyrosine-protein kinase transmembrane receptor ROR1","graph1":"Oncology","graph2":"Phase III","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncternal Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Oncternal Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Cirmtuzumab","moa":"||Inactive tyrosine-protein kinase transmembrane receptor ROR1","graph1":"Oncology","graph2":"Phase III","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncternal Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Oncternal Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Public Offering","leadProduct":"Cirmtuzumab","moa":"||Inactive tyrosine-protein kinase transmembrane receptor ROR1","graph1":"Oncology","graph2":"Phase II","graph3":"Oncternal Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Oncternal Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"Oncternal Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Public Offering","leadProduct":"Cirmtuzumab","moa":"||Inactive tyrosine-protein kinase transmembrane receptor ROR1","graph1":"Oncology","graph2":"Phase III","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncternal Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Oncternal Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Cirmtuzumab","moa":"||Inactive tyrosine-protein kinase transmembrane receptor ROR1","graph1":"Oncology","graph2":"Phase III","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncternal Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Oncternal Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Cirmtuzumab","moa":"||Inactive tyrosine-protein kinase transmembrane receptor ROR1","graph1":"Oncology","graph2":"Phase III","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncternal Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Oncternal Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Cirmtuzumab","moa":"||Inactive tyrosine-protein kinase transmembrane receptor ROR1","graph1":"Oncology","graph2":"Phase III","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncternal Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Oncternal Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Cirmtuzumab","moa":"||Inactive tyrosine-protein kinase transmembrane receptor ROR1","graph1":"Oncology","graph2":"Phase III","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncternal Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Oncternal Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Celularity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Collaboration","leadProduct":"Cirmtuzumab","moa":"||Inactive tyrosine-protein kinase transmembrane receptor ROR1","graph1":"Oncology","graph2":"Preclinical","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oncternal Therapeutics \/ Celularity","highestDevelopmentStatusID":"4","companyTruncated":"Oncternal Therapeutics \/ Celularity"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Public Offering","leadProduct":"Cirmtuzumab","moa":"Inactive tyrosine-protein kinase transmembrane receptor ROR1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Oncternal Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||Inactive tyrosine-protein kinase transmembrane receptor ROR1","graph1":"Oncology","graph2":"Phase III","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncternal Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Oncternal Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||Inactive tyrosine-protein kinase transmembrane receptor ROR1","graph1":"Oncology","graph2":"Phase III","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncternal Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Oncternal Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Karolinska Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||Inactive tyrosine-protein kinase transmembrane receptor ROR1","graph1":"Oncology","graph2":"Phase III","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncternal Therapeutics \/ Karolinska Institute","highestDevelopmentStatusID":"10","companyTruncated":"Oncternal Therapeutics \/ Karolinska Institute"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||Inactive tyrosine-protein kinase transmembrane receptor ROR1","graph1":"Oncology","graph2":"Phase III","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncternal Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Oncternal Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Pharmacyclics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Collaboration","leadProduct":"Ibrutinib","moa":"||Inactive tyrosine-protein kinase transmembrane receptor ROR1","graph1":"Oncology","graph2":"Phase III","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncternal Therapeutics \/ Pharmacyclics","highestDevelopmentStatusID":"10","companyTruncated":"Oncternal Therapeutics \/ Pharmacyclics"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||Inactive tyrosine-protein kinase transmembrane receptor ROR1","graph1":"Oncology","graph2":"Phase III","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncternal Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Oncternal Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Ho\u2019ola Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Divestment","leadProduct":"Ibrutinib","moa":"||Inactive tyrosine-protein kinase transmembrane receptor ROR1","graph1":"Oncology","graph2":"Phase III","graph3":"Oncternal Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"Infusion","sponsorNew":"Oncternal Therapeutics \/ Ho\u2019ola Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Oncternal Therapeutics \/ Ho\u2019ola Therapeutics"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"TK216","moa":"Protein C-ets-2 (ETS2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Oncternal Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"TK216","moa":"Protein C-ets-2 (ETS2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Oncternal Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"TK216","moa":"Protein C-ets-2 (ETS2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Oncternal Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"TK216","moa":"Protein C-ets-2 (ETS2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Oncternal Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Pharmacyclics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase III","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncternal Therapeutics \/ Pharmacyclics","highestDevelopmentStatusID":"10","companyTruncated":"Oncternal Therapeutics \/ Pharmacyclics"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"ONCT-808","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncternal Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"ONCT-808","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncternal Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"ONCT-808","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncternal Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"ONCT-808","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncternal Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Oncternal Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncternal Therapeutics \/ Oncternal Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Oncternal Therapeutics \/ Oncternal Therapeutics"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oncternal Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Oncternal Therapeutics \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals by Oncternal Therapeutics
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
